Insider Selling: Clovis Oncology Inc (CLVS) Insider Sells 3,000 Shares of Stock

Clovis Oncology Inc (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $54.09, for a total transaction of $162,270.00. Following the completion of the sale, the insider now directly owns 180,571 shares of the company’s stock, valued at $9,767,085.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Clovis Oncology Inc (NASDAQ:CLVS) opened at $54.15 on Monday. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94. Clovis Oncology Inc has a one year low of $45.42 and a one year high of $99.45.

A number of hedge funds and other institutional investors have recently bought and sold shares of CLVS. HealthCor Management L.P. increased its stake in Clovis Oncology by 50.4% in the fourth quarter. HealthCor Management L.P. now owns 973,840 shares of the biopharmaceutical company’s stock valued at $66,221,000 after purchasing an additional 326,420 shares during the period. Redmile Group LLC increased its stake in Clovis Oncology by 32.5% in the fourth quarter. Redmile Group LLC now owns 1,320,027 shares of the biopharmaceutical company’s stock valued at $89,762,000 after purchasing an additional 323,417 shares during the period. Franklin Resources Inc. increased its stake in Clovis Oncology by 13.8% in the fourth quarter. Franklin Resources Inc. now owns 2,634,401 shares of the biopharmaceutical company’s stock valued at $179,138,000 after purchasing an additional 318,931 shares during the period. Orbimed Advisors LLC increased its stake in Clovis Oncology by 13.5% in the third quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock valued at $196,826,000 after purchasing an additional 284,300 shares during the period. Finally, Millennium Management LLC acquired a new position in Clovis Oncology in the fourth quarter valued at $17,652,000.

A number of equities research analysts recently weighed in on CLVS shares. Barclays started coverage on shares of Clovis Oncology in a research report on Monday, October 23rd. They issued an “overweight” rating and a $105.00 price target for the company. JPMorgan Chase & Co. reissued a “buy” rating on shares of Clovis Oncology in a research report on Thursday, January 11th. Stifel Nicolaus reissued a “buy” rating and issued a $125.00 price target on shares of Clovis Oncology in a research report on Friday, November 3rd. Zacks Investment Research cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. Finally, Leerink Swann reissued an “outperform” rating and issued a $90.00 price target (down from $107.00) on shares of Clovis Oncology in a research report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. Clovis Oncology currently has a consensus rating of “Hold” and a consensus price target of $90.43.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://stocknewstimes.com/2018/02/19/insider-selling-clovis-oncology-inc-clvs-insider-sells-3000-shares-of-stock.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply